Human Patient-Derived Lung Cancer Organoid

Human patient-derived lung cancer organoid are three-dimensional tissue models established from primary tumor cells obtained through surgical resection or biopsy of lung cancer patients. These organoids preserve the histological architecture, molecular features, and intratumoral heterogeneity of the parental tumor, including driver mutations, oncogene expression, and drug response patterns. H&E and IHC analyses showed that LCOs mimic parental adenocarcinoma tissues with acinar or glandular patterns and retain expression of napsin-A, TTF-1, and CK7. Rigorous quality control ensures freedom from mycoplasma, bacteria, and fungi/yeast, alongside verification of genetic stability and functional performance. Human patient-derived lung cancer organoids provide a physiologically relevant platform for modeling tumor progression, studying resistance mechanisms, testing targeted therapies and immunotherapies, and enabling personalized precision medicine strategies in oncology research.